Swiss National Bank Trims Holdings in Celldex Therapeutics, Inc. $CLDX

Swiss National Bank trimmed its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 1.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 115,700 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the period. Swiss National Bank owned about 0.17% of Celldex Therapeutics worth $2,100,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in CLDX. GAMMA Investing LLC raised its stake in shares of Celldex Therapeutics by 6,665.9% in the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 2,933 shares during the period. Aquatic Capital Management LLC purchased a new stake in shares of Celldex Therapeutics in the 4th quarter valued at approximately $121,000. Hsbc Holdings PLC purchased a new stake in shares of Celldex Therapeutics in the 4th quarter valued at approximately $233,000. Ameriprise Financial Inc. acquired a new position in shares of Celldex Therapeutics in the fourth quarter valued at approximately $251,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Celldex Therapeutics in the first quarter valued at approximately $269,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on CLDX shares. Wells Fargo & Company dropped their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a report on Wednesday. UBS Group dropped their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Friday, May 9th. The Goldman Sachs Group dropped their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a report on Friday, May 9th. HC Wainwright dropped their price objective on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Citigroup dropped their price objective on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Celldex Therapeutics Trading Up 2.0%

Shares of Celldex Therapeutics stock opened at $22.46 on Friday. The company has a fifty day simple moving average of $22.12 and a 200-day simple moving average of $20.64. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $47.00. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -7.46 and a beta of 1.22.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.13 million. On average, analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.